Substance / Medication

Nilotinib

Overview

Active Ingredient
nilotinib
RxNorm CUI
662281
Labeler: Novadoz Pharmaceuticals LLCUpdated: 2025-11-20T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

see Warnings and Precautions (5.2) [] see Warnings and Precautions (5.2 5.3 5.7 5.12) [,,,] Nilotinib prolongs the QT interval. Prior to nilotinib administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies. Obtain ECGs to monitor the QTc at baseline, seven da

Contraindications

When this intervention should not be used

see Boxed Warning []. Nilotinib is contraindicated in patients with hypokalemia, hypomagnesemia, or long QT syndrome

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Nilotinib in Parkinson's disease: A systematic review and meta-analysis.
Xie Xiaolu, Yuan Ping, Kou Liqiu et al. · Front Aging Neurosci · 2022
PMID: 36248007Meta-AnalysisFull text (PMC)
Efficacy evaluation of nilotinib treatment in different genomic subtypes of gastrointestinal stromal tumors: A meta-analysis and systematic review.
Zhao Zekun, Zhang Jie, Zhang Wenbing et al. · Curr Probl Cancer · 2021
PMID: 33495025Meta-Analysis
Utility of Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
García-Ferrer Manuel, Wojnicz Aneta, Mejía Gina et al. · Clin Ther · 2019
PMID: 31812340Meta-Analysis
Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis.
Signorovitch James, Ayyagari Rajeev, Reichmann William M et al. · Cancer Treat Rev · 2014
PMID: 24112812Meta-Analysis
Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization.
Drucker Aaron M, Wu Shenhong, Busam Klaus J et al. · Eur J Haematol · 2013
PMID: 23240881Meta-Analysis
Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
Rogers G, Hoyle M, Thompson Coon J et al. · Health Technol Assess · 2012
PMID: 22551803Meta-AnalysisFull text (PMC)
Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study.
Matsumura Itaru, Ohtake Shigeki, Atsuta Yoshiko et al. · Blood Adv · 2024
PMID: 38968156RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Nilotinib (substance)
SNOMED CT
427941004
UMLS CUI
C1721377
RxNorm CUI
662281
Labeler
Novadoz Pharmaceuticals LLC

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.